Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
PRE 14A
Preliminary proxy
3 Apr 24
8-K
Carlyle Appoints Afsaneh M. Beschloss as an Independent Director
3 Apr 24
8-K
Carlyle Names Lindsay LoBue as Chief Operating Officer
27 Mar 24
8-K
Carlyle Reports Fourth Quarter and Full-Year 2023 Financial Results
7 Feb 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Carlyle Reports Third Quarter 2023 Financial Results
6 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Carlyle Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Carlyle Names John Redett as Chief Financial Officer and Head of Corporate Strategy
20 Jun 23
S-8
Registration of securities for employees
16 Jun 23
8-K
Departure of Directors or Certain Officers
1 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Carlyle Reports First Quarter 2023 Financial Results
3 May 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
8-K
Carlyle Appoints Sharda Cherwoo as an Independent Director
26 Apr 23
ARS
2022 FY
Annual report to shareholders
12 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
PRE 14A
Preliminary proxy
28 Mar 23
S-3ASR
Automatic shelf registration
22 Mar 23
10-K/A
2022 FY
Annual report (amended)
22 Mar 23
8-K
Peter Clare to Retire from Carlyle and as a Member of the Board of Directors after 31 years at the Firm
27 Feb 23
S-8
Registration of securities for employees
13 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Carlyle Announces Fourth Quarter and Full Year 2022 Financial Results
6 Feb 23
8-K
Harvey Schwartz Named CEO of Carlyle and Member of the Board
6 Feb 23
S-8
Registration of securities for employees
20 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Carlyle Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Carlyle Announces Senior Leadership Changes
8 Aug 22
424B3
Prospectus supplement
1 Aug 22
8-K
Other Events
1 Aug 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Carlyle Reports Second Quarter 2022 Financial Results
27 Jul 22
8-K
Departure of Directors or Certain Officers
7 Jul 22
Latest ownership filings
4
CommScope Holding Company, Inc.
2 Apr 24
SC 13G
Q32 Bio Inc.
29 Mar 24
4
HARVEY M SCHWARTZ
5 Mar 24
SC 13D/A
Carlyle Group Management L.L.C.
5 Mar 24
4
HARVEY M SCHWARTZ
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Jasper Therapeutics, Inc.
12 Feb 24
SC 13D/A
Jasper Therapeutics, Inc.
12 Feb 24
SC 13G/A
ZoomInfo Technologies Inc.
12 Feb 24
SC 13G/A
MKS INSTRUMENTS INC
12 Feb 24
SC 13G/A
Phathom Pharmaceuticals, Inc.
12 Feb 24
SC 13G/A
HilleVax, Inc.
12 Feb 24
SC 13G/A
MORGAN STANLEY
12 Feb 24
SC 13G
Capital World Investors
9 Feb 24
4
Jeffrey W. Ferguson
8 Feb 24
4
John C. Redett
8 Feb 24
4
Charles Elliott Jr. Andrews
8 Feb 24
4
Christopher Finn
8 Feb 24
SC 13D/A
Adicet Bio, Inc.
7 Feb 24
4
Jeffrey W. Ferguson
5 Feb 24
4
Christopher Finn
5 Feb 24
13F-HR
Quarterly holdings report by institutional manager
2 Feb 24
SC 13G
BlackRock Inc.
25 Jan 24
SC 13D/A
CommScope Holding Company, Inc.
3 Jan 24
4
CommScope Holding Company, Inc.
3 Jan 24
4
HARVEY M SCHWARTZ
19 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
4
HARVEY M SCHWARTZ
1 Dec 23
13F-HR
Quarterly holdings report by institutional manager
3 Nov 23
SC 13D/A
SOLENO THERAPEUTICS INC
16 Oct 23
SC 13D/A
SOLENO THERAPEUTICS INC
3 Oct 23
4
SOLENO THERAPEUTICS INC
2 Oct 23
3
John C. Redett
2 Oct 23
4
CommScope Holding Company, Inc.
2 Oct 23
SC 13G
Complete Solaria, Inc.
22 Sep 23
SC 13D/A
Carlyle Credit Income Fund
14 Sep 23
4
Carlyle Credit Income Fund
14 Sep 23
4
Carlyle Credit Income Fund
30 Aug 23
SC 13D/A
Carlyle Credit Income Fund
30 Aug 23